Reduction in vesicant-induced cellular inflammation and hyperalgesia by local injection of corticotropin releasing factor in rabbit eyelid

Inflammation Research

Volumn 51, Issue 1, 2002, Pages 16-23

  McLoon, L K ^a   Sandnas, A M ^a   Nockleby, K J ^a   Wirtschafter, J D ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Macrophages Peripheral administration; Peripheral inflammation; Sensory afferents; Skin

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DOXORUBICIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EYELID REFLEX; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; NONHUMAN; RABBIT;

EID: 0036164362     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000277     Document Type: Article

References (32)

1. Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm
2. Skin ulcers due to Adriamycin
3. Adriamycin extravasation
4. Long persistence of doxorubicin in human skin after extravasation
5. Corticotropin-releasing factor inhibition of substance P-induced vascular leakage in rats: Possible sites of action
6. Corticotropin-releasing factor: An inhibitor of vascular leakage in rat skeletal muscle and brain cortex after injury
7. Corticotropin-releasing factor inhibits thermal injury
8. Local injections of corticotropin releasing factor reduce doxorubicin-induced acute inflammation in the eyelid
9. Corticotropin-releasing factor inhibits the response of trigeminal neurons to noxious heat
10. Expression of corticotropin-releasing factor in inflamed tissue is required for intrinsic peripheral opioid analgesia
11. Doxorubicin chemomyectomy: Injection of monkey orbicularis oculi results in selective muscle injury
12. The orbicularis oculi muscle fibers are relatively short and heterogeneous in length
13. CRF and urocortin decreased brain stimulation reward in the rat: Reversal by a CRF receptor antagonist
14. Cyclosporin protects the eyelid skin from injury after injection of doxorubicin
15. Cutaneous innervation in man visualized with protein gene product 9.5 (PGP 9.5) antibodies
16. Antidotes to vesicant chemotherapy extravasations
17. Bipolar-shape response of human neutrophils to corticotropin-releasing factor
18. Corticotropin-releasing factor receptor 1 in mouse spleen: Expression after immune stimulation and identification of receptor-bearing cells
19. Induction of beta-endorphin secretion by lymphocytes after subcutaneous administration of corticotropin-releasing factor
20. Corticotropin releasing factor modulates interleukin-1-induced prostaglandin synthesis in fibroblasts: Receptor binding and effects of antagonists
21. Use of blocking antibodies as probes for in vivo functions of chemokines
22. Expression of receptors for corticotropin-releasing factor in the vasculature of pregnant rats
23. Corticotropin-releasing factor decreases vasogenic brain edema
24. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema
25. Treatment of periorbital edema with human corticotropin-releasing factor after blepharoplasty
26. Reduction of ischemic reperfusion edema with corticotropin-releasing factor (CRF) in rat hind limb replantation
27. Modulation of the inflammatory response by corticotropin-releasing factor
28. Corticotropin-releasing factor inhibits antigen-induced plasma extravasation in airways
29. Proopiomelanocortin, corticotropin releasing hormone and corticotropin releasing hormone receptor genes are expressed in human skin
30. Local upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb inflammation
31. Interleukin 1 beta and corticotropin releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue
32. Opioid and non-opioid stress analgesia from cold water swim: Importance of stress severity